Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.2000 (-1.01%) ($12.2000 - $12.2000) on Thu. Sep. 21, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.32% (three month average) | RSI | 42 | Latest Price | $12.2000(-1.01%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(70%) IBB(64%) ARKG(59%) IWO(47%) BWX(46%) | Factors Impacting FOLD price | FOLD will decline at least -1.16% in a week (0% probabilities). TBT(-34%) UUP(-17%) VXX(-10%) URA(-4%) VIXM(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.16% (StdDev 2.32%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $12.82 | 5 Day Moving Average | $12.68(-3.79%) | 10 Day Moving Average | $12.85(-5.06%) | 20 Day Moving Average | $12.82(-4.84%) | To recent high | -11.5% | To recent low | 3.6% | Market Cap | $3.15b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |